Complications of Topical Timolol in the Management of Infantile Hemangiomas: A Systematic Review.

Article

Date Published October 31, 2025

Pediatric Medicine
Lyudmyla Susla
Topical timolol is generally well tolerated for IH treatment, with systemic adverse effects occurring infrequently. Preterm infants and those with ulcerated or deep IHs may be at increased risk for complications. Further research is warranted to better define risk factors for systemic absorption and establish optimal dosing guidelines for safe use in infants.
Update This Listing

Help us provide the most up-to-date information about this project.

Contact Us
Questions?

For questions about these research projects please email us.

Contact Us
This summary was generated by AACOM. The researchers and authors of this work were not involved in the curation of this summary.